Patents by Inventor Robert T. Brooke

Robert T. Brooke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230346952
    Abstract: The present invention provides tetrahydrocannabinol glycoside and cannabidiol glycoside prodrugs and pharmaceutical compositions comprising these compounds, and their use for the site-specific delivery of tetrahydrocannabinol or cannabidiol. Also provided are processes for the preparation of purified tetrahydrocannabinol glycoside and cannabidiol glycoside prodrugs.
    Type: Application
    Filed: March 13, 2023
    Publication date: November 2, 2023
    Applicant: Graphium Biosciences, Inc.
    Inventors: Brandon J. ZIPP, Janee’ M. HARDMAN, Robert T. BROOKE, Tyrel R. DEUTSCHER
  • Patent number: 11730795
    Abstract: A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4/CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: August 22, 2023
    Assignee: INTERVENE IMMUNE INC.
    Inventors: Gregory M. Fahy, Robert T. Brooke
  • Publication number: 20220168428
    Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.
    Type: Application
    Filed: November 16, 2021
    Publication date: June 2, 2022
    Applicant: Graphium Biosciences, Inc.
    Inventors: Brandon J. Zipp, Janee M. Hardman, Robert T. Brooke
  • Patent number: 11207414
    Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: December 28, 2021
    Assignee: Graphium Biosciences, Inc.
    Inventors: Brandon J. Zipp, Janee M. Hardman, Robert T. Brooke
  • Publication number: 20200254066
    Abstract: A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4/CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.
    Type: Application
    Filed: August 7, 2018
    Publication date: August 13, 2020
    Inventors: Gregory M. Fahy, Robert T. Brooke
  • Publication number: 20180264122
    Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 20, 2018
    Applicant: Vitality Biopharma, Inc.
    Inventors: Brandon J. Zipp, Janee M. Hardman, Robert T. Brooke